Elastatinal |
Katalog-Nr.GC18191
One-Click Copy Product Info
|
Elastatinal ist ein potenter und kompetitiver Elastase-Inhibitor mit einem Ki von 0,21 μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 51798-45-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Elastatinal is a potent inhibitor of pancreatic elastase (Ki = 240 nM) that is produced by various species of Actinomycetes. [1] It more strongly inhibits pancreatic elastase versus the leukocyte-derived enzyme. [2] [3] Elastatinal reduces electrophoretic mobilities of 2A proteinases from poliovirus and human rhinovirus 14 in a dose-dependent manner, indicating substrate recognition by 2A proteinases is similar to that of pancreatic elastases.[4] It can also inhibit elastase-like protease collagenolytic protease from C. maenas digestive glands.[5]
Reference:
[1]. Umezawa, H. Structures and activities of protease inhibitors of microbial origin. Methods Enzymol. 45, 678-695 (1976).
[2]. Feinstein, G., Malemud, C.J., and Janoff, A. The inhibition of human leucocyte elastase and chymotrypsin-like protease by elastatinal and chymostatin. Biochim Biophys. Acta. 429(3), 925-932 (1976).
[3]. Okumura, Y., Ogawa, K., and Uchiya, K. Characterization and primary structure of elastase inhibitor, AFLEI, from Aspergillus flavus. Nishon Ishinkin Gakkai Zasshi 48(1), 13-18 (2007).
[4]. Molla, A., Hellen, C.U.T., and Wimmer, E. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J. Virol. 67(8), 4688-4695 (1993).
[5]. Roy, P., Colas, B., and Durand, P. Purification, kinetical and molecular characterizations of a serine collagenolytic protease from greenshore crag (Carcinus maenas) digestive gland. Comp. Biochem. Physiol. Biochem. Mol. Biol. 115(1), 87-95 (1996).
| Cas No. | 51798-45-9 | SDF | |
| Chemical Name | (2S)-2-[(4S)-2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl]-N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]glycyl-N1-[(1S)-1-methyl-2-oxyethyl]-L-glutamamide | ||
| Canonical SMILES | NC1=NCC[C@]([C@H](NC(N[C@H](C(O)=O)CC(C)C)=O)C(N[C@H](C(N[C@@H](C)C=O)=O)CCC(N)=O)=O)([H])N1 | ||
| Formula | C21H36N8O7 | M.Wt | 512.6 |
| Löslichkeit | 20mg/mL in DMSO, 33mg/mL in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9508 mL | 9.7542 mL | 19.5084 mL |
| 5 mM | 390.2 μL | 1.9508 mL | 3.9017 mL |
| 10 mM | 195.1 μL | 975.4 μL | 1.9508 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)